LUMINOS-103 | Istari Oncology

A basket trial investigating lerapolturev (formerly PVSRIPO) alone or in combination with immune checkpoint inhibitors in multiple solid tumor types

A basket trial of lerapolturev (formerly PVSRIPO) and lerapolturev in combination with anti–PD-1/L1 checkpoint inhibitors in multiple solid tumor types

LUMINOS-103 Study Design

DLT, dose-limiting toxicity; DSMC, Data Safety Monitoring Committee; NMIBC, non-muscle-invasive bladder cancer.

LUMINOS-103 Study Design

DLT, dose-limiting toxicity; DSMC, Data Safety Monitoring Committee; HNSCC, head and neck squamous cell cancer; MIBC, muscle-invasive bladder cancer.

LUMINOS-103 (NCT04690699) is a multicenter, open-label, single-arm phase 1/2 basket study designed to enable investigation of the efficacy and safety of lerapolturev in several solid tumor types. The study is currently investigating the ability of intravesicular lerapolturev monotherapy to successfully infect cancerous bladder tissue among patients with low-intermediate risk NMIBC undergoing planned transurethral resection of bladder tumor (TURBT) or cystectomy.

Cohort

Tumor type

Setting

A

MIBC

Neoadjuvant treatment of patients with MIBC who refuse or are ineligible for cisplatin

B

MIBC

First-line treatment of unresectable or metastatic MIBC

C

HNSCC

Neoadjuvant treatment of patients with resectable, locally advanced HNSCC

D

HNSCC

First-line treatment of unresectable or metastatic HNSCC

Get additional information

Please contact us or email LUMINOS-103@istarioncology.com.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.